Regardless of the exact mechanisms, given that elevated expression of c-Myc is ubiquitously observed in many B cell malignancies [45], our findings suggest that AD 198 may have wide therapeutic application in B cell neoplasms. The gene discussed is MYC; the disease is B-cell neoplasm.